Loading…
ENvue Medical, Inc. is projected to rise to $0.3502 by 2027, a +2% move from its current price of $0.3434. FEED is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/4/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 5 | $0.3283 | $0.3435 | $0.3595 | +0.03% |
| Aug 6 | $0.3223 | $0.3436 | $0.3664 | +0.06% |
| Aug 7 | $0.3177 | $0.3437 | $0.3718 | +0.10% |
| Aug 8 | $0.314 | $0.3438 | $0.3765 | +0.13% |
| Aug 9 | $0.3108 | $0.344 | $0.3807 | +0.16% |
| Aug 10 | $0.3079 | $0.3441 | $0.3845 | +0.19% |
| Aug 11 | $0.3052 | $0.3442 | $0.3881 | +0.23% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $0.3052 | $0.3442 | $0.3881 | +0.23% |
| Week 2 | $0.2911 | $0.345 | $0.4088 | +0.45% |
| Week 3 | $0.2808 | $0.3457 | $0.4257 | +0.68% |
| Week 4 | $0.2725 | $0.3465 | $0.4406 | +0.91% |
| Week 5 | $0.2655 | $0.3473 | $0.4543 | +1.14% |
| Week 6 | $0.2594 | $0.3481 | $0.4671 | +1.37% |
| Week 7 | $0.2539 | $0.3489 | $0.4794 | +1.60% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
ENvue Medical, Inc., through its subsidiaries, focuses on non-invasive biological response-activating devices that target biofilm prevention, pain therapy, wound healing, and at home administration without medical professional assistance. Its product portfolio includes UroShield, an ultrasound-based product that is designed to prevent bacterial colonization and biofilm in urinary catheters, increase antibiotic efficacy, and decrease pain and discomfort associated with urinary catheter use. The company also offers UroShield Ultra, which is designed to prevent bacterial colonization and biofilm formation in urinary catheters; PainShield, a patch-based therapeutic ultrasound technology to treat pain, muscle spasm, and joint contractures; PainShield MD, a single patch-based therapeutic ultrasound technology to treat pain, muscle spasm, and joint contractures; PainShield Plus, a dual patch-based therapeutic ultrasound technology; and WoundShield, a patch-based therapeutic ultrasound device intended to facilitate tissue regeneration and wound healing.
The company sells its products directly to patients, as well as through distributor agreements in the United States, Europe, Australia, Israel, New Zealand, and internationally. ENvue Medical, Inc. was formerly known as NanoVibronix, Inc.
and changed its name to ENvue Medical, Inc. in December 2025. The company was incorporated in 2003 and is based in Tyler, Texas.
ENvue Medical, Inc. (FEED) operates in the Healthcare sector and trades with a current price of $0.3156. The stock has a market capitalization of $1.92M and is ranked 5446. These figures place the company among smaller-cap healthcare stocks with a specialized device portfolio.
A major floor 82.5% below — a decisive break under it would weaken the trend.
The nearest floor, 8.0% below — buyers have tended to step in here.
The nearest ceiling, 103.8% above — a clean break opens room to run.
A major ceiling 668.8% above — clearing it would confirm fresh momentum.
Key FEED support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of FEED market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $0.3334 | Buy | $0.3336 | Buy |
| MA 10 | $0.3534 | Sell | $0.3596 | Sell |
| MA 20 | $0.415 | Sell | $0.4216 | Sell |
| MA 50 | $0.631 | Sell | $0.6599 | Sell |
| MA 100 | $1.10 | Sell | $1.27 | Sell |
| MA 200 | $2.28 | Sell | $5.16 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 24.29 | Buy |
| Stoch RSI (14) | 0.00 | Buy |
| CCI (20) | -107.14 | Sell |
| Williams %R (14) | -100.00 | Info |
| MACD (12,26,9) | 0.01 | Buy |
| ROC (12) | -25.65 | Sell |
| Bollinger %B (20,2) | 0.15 | Neutral |
| Stochastic %K (14) | 0.00 | Buy |
| TRIX (15) | -2.40 | Sell |
| Awesome (5,34) | -0.18 | Sell |
| Ultimate (7,14,28) | 17.25 | Buy |
| Momentum (10) | -0.10 | Sell |
| Aroon Osc (25) | -96.00 | Sell |
| Hull MA (9) | 0.31 | Buy |
| ADX (14) | 44.14 | Sell |
| ATR (14) | 0.02 | Info |
The near-term picture shows a NEUTRAL sentiment with RSI14 at 20. The market trades below its key moving averages, with SMA50 at $0.631 and SMA200 at $2.28. Support is identified at $0.316 and resistance at $0.70, framing a tight near-term range.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $0.316 | $0.3434 | $0.5148 | 0% | Neutral | |
| $0.2626 | $0.3502 | $0.5024 | +2% | Neutral | |
| $0.2879 | $0.4038 | $0.6135 | +18% | Neutral | |
| $0.3362 | $0.4921 | $0.781 | +43% | Bullish | |
| $0.3524 | $0.536 | $0.882 | +56% | Bullish | |
| $0.3205 | $0.5049 | $0.8574 | +47% | Bullish | |
| $0.2766 | $0.4507 | $0.7868 | +31% | Bullish | |
| $0.2719 | $0.4573 | $0.8185 | +33% | Bullish | |
| $0.2631 | $0.4563 | $0.8354 | +33% | Bullish | |
| $0.3204 | $0.5726 | $1.07 | +67% | Bullish | |
| $0.2582 | $0.5315 | $1.08 | +55% | Bullish | |
| $0.6381 | $1.42 | $3.26 | +313% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $0.316 | $0.3434 | $0.438 | +0.00% |
| September 2026 | $0.3042 | $0.3666 | $0.459 | +6.76% |
| October 2026 | $0.2901 | $0.3537 | $0.4506 | -3.52% |
| November 2026 | $0.2963 | $0.3648 | $0.4712 | +3.13% |
| December 2026 | $0.3169 | $0.3936 | $0.5148 | +7.90% |
Click any year to see its month-by-month FEED forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
ENvue Medical, Inc.'s 2026 outlook centres on $0.3434, within a $0.316 to $0.5148 range. That marks a 0% change versus current levels. A consolidation phase looks the most probable path here.
By 2027, FEED could reach as high as $0.5024, with a base case around $0.3502 and support toward $0.2626 — roughly +2% from $0.3434. Price action looks broadly range-bound.
Expect FEED to range from $0.2879 to $0.6135 through 2028. The $0.4038 average target implies a +18% move from current prices. That is up +15% on the projected 2027 average. A consolidation phase looks the most probable path here.
The FEED price prediction for 2029 points to an average of $0.4921 (low $0.3362, high $0.781) — a potential gain of +43% on today's $0.3434. Momentum favours further upside here.
In 2030, FEED is projected to trade between $0.3524 and $0.882, averaging $0.536 — a potential gain of +56% from today's $0.3434. That is up +9% on the projected 2029 average. Buyers look set to stay in control over this stretch.
ENvue Medical, Inc.'s 2031 outlook centres on $0.5049, within a $0.3205 to $0.8574 range. That is -6% versus the projected 2030 average. That marks a +47% change versus current levels. Momentum favours further upside here.
By 2032, FEED could reach as high as $0.7868, with a base case around $0.4507 and support toward $0.2766 — roughly +31% from $0.3434. Buyers look set to stay in control over this stretch.
Expect FEED to range from $0.2719 to $0.8185 through 2033. The $0.4573 average target implies a +33% move from current prices. That is up +1% on the projected 2032 average. Momentum favours further upside here.
The FEED price prediction for 2034 points to an average of $0.4563 (low $0.2631, high $0.8354) — a potential gain of +33% on today's $0.3434. Buyers look set to stay in control over this stretch.
In 2035, FEED is projected to trade between $0.3204 and $1.07, averaging $0.5726 — a potential gain of +67% from today's $0.3434. That is up +25% on the projected 2034 average. Momentum favours further upside here.
ENvue Medical, Inc.'s 2040 outlook centres on $0.5315, within a $0.2582 to $1.08 range. That is -7% versus the projected 2035 average. That marks a +55% change versus current levels. Buyers look set to stay in control over this stretch.
By 2050, FEED could reach as high as $3.26, with a base case around $1.42 and support toward $0.6381 — roughly +313% from $0.3434. Momentum favours further upside here.
Investing $1,000 in FEED today (≈ 2,912.055911 FEED) could be worth
$4,129.54
+$3,129.54 (+313%) by 2050 · US Dollar
Based on the average projected FEED price of $1.42 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in FEEDwould be worth at today's price.
$1,000 invested in FEED on Jul 31, 2025 (≈ 121.065372 FEED) would be worth
$41.57
-$958.43 (-95.8%) today · 0.04× · US Dollar
Based on a FEED entry price of $8.26 vs. today's $0.3434.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $0.382 | $898.95 | -10.1% |
| 1 month ago | $0.57 | $602.46 | -39.8% |
| 3 months ago | $1.19 | $288.57 | -71.1% |
| 6 months ago | $2.42 | $141.9 | -85.8% |
| 1 year ago | $8.26 | $41.57 | -95.8% |
| All time (5.0y) ago | $5,390 | $0.06 | -100.0% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our FEED forecast.
Our base-case forecast reaches $0.69 around 2050.
Implied market cap at $0.69: $4.2M
The year-by-year forecast outlines a bullish trajectory beginning in the late 2020s. For 2026 the forecast is min $0.3156, avg $0.3156, max $0.4741 with ROI 0 and NEUTRAL sentiment. From 2027 onward the averages creep higher: 2027 avg $0.3208 (ROI 1.6), 2028 avg $0.3719 (ROI 17.8), and 2029 avg $0.4533 (ROI 43.6), with 2030 avg $0.4919 (ROI 55.9).
The outlook continues with 2031 avg $0.4647 (ROI 47.2), 2032 avg $0.4144 (ROI 31.3), 2033 avg $0.4197 (ROI 33), 2034 avg $0.4206 (ROI 33.3), and 2035 avg $0.5266 (ROI 66.9). Beyond that, 2040 is forecast at avg $0.4893 (ROI 55) and max $0.9973, while 2050 projects min $0.5873, avg $1.31, max $3.00 with ROI 313.5 and a BULLISH sentiment. These figures imply a long-run bullish path but remain estimates, not guarantees, and outcomes may vary.
Tap a question to reveal the answer.
Avg price: $0.4919; Min: $0.3234; Max: $0.8096; ROI: 55.9%; Sentiment: BULLISH.
Forecasts show bullish sentiment from 2029 onward with 2029 avg $0.4533 and max $0.7195, 2030 avg $0.4919, and 2050 avg $1.31 with a max of $3.00 and ROI as high as 313.5%. These are estimates and not guarantees, and actual results may vary.
Min $0.3156; Avg $0.3156; Max $0.4741; ROI 0; Sentiment: NEUTRAL.
Yes, the forecast shows a max of $3.00 in 2050 with a min of $0.5873 and an avg of $1.31, corresponding to a ROI of 313.5 and a BULLISH sentiment.
Annualized volatility is 90.
ENvue Medical, Inc. Community Discussion
0Share your ENvue Medical, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.